Eli Lilly Reports Strong Q1 2026 Earnings with Revenue Growth Driven by Key Products

Eli Lilly (LLY) reported a 56% revenue increase in Q1 2026 compared to the same period in 2025, driven by strong performance from products like Zepbound and Mounjaro. The company also highlighted significant international growth and a gross margin of 82.6%, despite a slight decline.

By Motley Fool Transcribing · Motley Fool · April 30, 2026, 15:31 UTC

Tickers: $LLY

Topics: Earnings Report Market Expansion Product Sales Revenue Growth

Read the full article at Motley Fool

More World news

Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact Seeking Alpha · November 12, 2026, 16:53 UTC
Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth Seeking Alpha · November 12, 2026, 16:50 UTC
EyePoint Pharmaceuticals Announces Strategic Shift to DURAVYU DME Following Phase III Wet AMD Trial Failures Seeking Alpha · November 12, 2026, 16:50 UTC
Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC